2Lavaissiere L, Jia S, Nishiyama M, et al, Overexpression of human aspartyl (asparaginyl) β-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest, 1996, 98(6): 1313-1323.
3Jones LR, Zhang L, Sanborn K, et al. Purification, primary structure, and immunological characterization of the 26-kDa calsequestrin binding protein (junctin) from cardiac junctional sarcoplasmic reticulum. J Biolog Chemis, 1995, 270(51): 30787-30796.
4Ince N, de la Monte SM, and Wands JR. Overexpression of human aspartyl (asparaginyl) b-hydroxylase is associated with malignant transformation. Cancer Res, 2000, 60(5): 1261-1266.
5Maeda T, Sepe P, Lahousse S, et al. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyJ) β-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol, 2003, 38(5): 615-622.
6Takashi M, Ken-ichi T, Shin-ichi A, et al. Clinicopathological correlates of aspartyl (asparaginyl)β-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prevent, 2004, 28(5): 313-318.
7Feldmann G, Nattermann J, Nischalke HD, et al. Detection of human aspartyl (asparaginyl) β-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. Endoscopy, 2006, 38(6): 604-609.
8Palumbo KS, Wands JR, Safran H, et al. Human aspartyl (asparaginyl) β-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas, 2002, 25(1): 39-44.
10Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol, 1998, 72(10): 8430-8436.
